Nanoform is delighted to announce the initiation of a technology evaluation of Nanoform’s Proprietary CESSTM Technology across a range of AstraZeneca’s proprietary pharmaceutical products.
The initiation of this study is to assess the added value that Nanoform’s proprietary technology could deliver across the pharmaceutical value chain.
Commenting on the agreement, Edward Hæggström, CEO of Nanoform said:
We have always believed that our technology has significant value to offer the Pharma industry, particularly in reducing clinical attrition rates by nanonizationTM to increase dissolution rates of poorly soluble APIs and overcome significant bioavailability challenges, as evidenced by the work conducted between us and our pharmaceutical partners.
Producing tailored nanoparticles <200nm from solution, in a controlled and reproducible manner, with good yield and without the need for excipients is highly challenging to do by current pharmaceutical manufacturing techniques or processes.
This is the first step of hopefully a long and successful relationship between our two companies and we look forward to working closely with AZ to support their early development needs and validating the value of our technology for their products
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services.
For more information please visit https://www.nanoform.fi/